Zika virus has an oncolytic activity against human glioblastoma U87 cells

Glioblastoma is a highly lethal brain cancer. Virotherapy with the use of oncolytic viruses has since recently been regarded as a promising approach for the clinic treatment of human glioblastomas. The purpose of this work was to perform a primary evaluation of the Zika virus as a potential oncolytic agent against glioblastomas. In vitro experiments showed that the Zika virus strain MR 766 is able to selectively infect and lyse neoplastic cells of the human glioblastoma cell line U87 MG. The selectivity index (SI, the ratio of infectious titer for tumor cells to titer on normal untransformed cells) was 2 . 10(2). The selectivity of the replicative activity of Zika virus in relation to U87 MG glioblastoma cells was additionally confirmed by indirect immunofluorescence. Using the model of immunodeficient SCID mice with subcutaneous xenografts of human glioblastoma U87 MG, a strong antitumor activity of the Zika virus under a course (daily for 4 days) of intratumoral administration of 5 . 10(5) TCID50 of Zika virus was shown. Treatment with Zika virus resulted in more than a 10-fold reduction in mean volumes of tumors. The tumor growth inhibition index was 92.63 %. Recurrences (metastases) of tumor re-growth were not registered within 64 days of observation. This result demonstrated the prospect of further in-depth studies of the Zika virus as a potential oncolytic agent against human glioblastomas.